Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers
She will provide strategic advice and scientific leadership to support clients in clinical development, registration strategy, submission, early post-approval strategy
Acquisition expands Merck’s growing hematology portfolio
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.
The combination of Optym, Emmes' ophthalmology certification unit, and Clinical Edge will make the organization a leader in ophthalmic certification and training services
Subscribe To Our Newsletter & Stay Updated
